Dyne Therapeutics, Inc.
We are building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. We are utilizing our proprietary FORCE platform to overcome the current limitations of muscle tissue delivery and advance modern oligonucleotide therapeutics for muscle diseases.
Using our FORCE platform, we are assembling a broad portfolio of muscle disease therapeutics, including our lead programs in myotonic dystrophy type 1, or DM1, Duchenne muscular dystrophy, or DMD, and facioscapulohumeral dystrophy, or FSHD. In addition, we plan to expand our portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases, including some with larger patient populations. Our programs are currently all in the preclinical stage. We expect to submit investigational new drug, or IND, applications to the U.S. Food and Drug Administration, or FDA, for product candidates in each of our DM1, DMD and FSHD programs between the fourth quarter of 2021 and the fourth quarter of 2022.
|Address||830 Winter Street, Waltham, MA 02451, US|
|Phone Number||(781) 786-8230|
|View Prospectus:||Dyne Therapeutics, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-28.2 mil (last 12 months)|
|Price range||$19.00 - $19.00|
|Est. $ Volume||$232.8 mil|
|Manager / Joint Managers||J.P. Morgan/ Jefferies/ Piper Sandler/ Stifel|
|Expected To Trade:||9/17/2020|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|